Drug Trial Radar · NCT01266850
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
Last checked: Nov 20, 2026Latest source record: Oct 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,384
Actual
Start
Mar 2011
Primary completion
Oct 2013
Study completion Mar 2014
Sponsor
- Sponsor type
- NIH
- First posted
- Dec 24, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 weeks, up to 14 weeks
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Rotavirus, sometimes called the "stomach flu," is the most common cause of severe diarrhea in children. Vaccines can prevent many types of infections and work by causing the body to make proteins called antibodies that fight infection. For some vaccines, more than one vaccination is needed so that the body will make enough antibodies to fight infection. The vaccines (RotaTeq® or Rotarix® oral vaccines) given in this study are recommended for infants by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). These vaccines require either 2 or 3 vaccinations to be effective. Healthy infants between 6 weeks and 14 weeks, 6 days of age at Visit 1 will participate for about 10-12 months. Study procedures include reaction assessment and blood sample.
Conditions
- Rotavirus Infection
Interventions
Rotarix®Biological
Each 1-mL dose of Rotarix® contains a suspension of at least 10\^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
RotaTeq®Biological
2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10\^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10\^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA AssayTime frame: 3-6 weeks after the last vaccination
- Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the 89-12 IgA AssayTime frame: 3-6 weeks after the last vaccination
- Geometric Mean Serum Anti-rotavirus IgA TiterTime frame: 3-6 weeks after the last dose of vaccine
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Kaiser Permanente Vaccine Study Center
Oakland, California
Children's Hospital & Research Center Oakland - Primary Care Clinic
Oakland, California
Emory Children's Center - Pediatric Infectious Diseases
Atlanta, Georgia
University of Iowa - Vaccine Research & Education Unit
Iowa City, Iowa
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore
Baltimore, Maryland
Children's Mercy Hospital and Clinics - Infectious Diseases
Kansas City, Missouri
Duke Translational Medicine Institute - Clinical Vaccine Unit
Durham, North Carolina
Primary Physicians Research Inc. - Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center
Nashville, Tennessee
The University of Texas Medical Branch - Sealy Center for Vaccine Development (SCVD)
Galveston, Texas
Baylor College of Medicine - Molecular Virology and Microbiology
Houston, Texas
Group Health Research Institute - Seattle
Seattle, Washington
Seattle Children's Hospital - Infectious Diseases
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.